OBSTETRICS: MEDICAL COMPLICATIONS OF PREGNANCYContinuous Glucose Monitoring in Pregnant Women With Type 1 Diabetes (CONCEPTT): A Multicenter International Randomised Controlled TrialFeig, Denice S.; Donovan, Lois E.; Corcoy, Rosa; Murphy, Kellie E.; Amiel, Stephanie A.; Hunt, Katharine F.; Asztalos, Elizabeth; Barrett, Jon F. R.; Sanchez, J. Johanna; de Leiva, Alberto; Hod, Moshe; Jovanovic, Lois; Keely, Erin; McManus, Ruth; Hutton, Eileen K.; Meek, Claire L.; Stewart, Zoe A.; Wysocki, Tim; O'Brien, Robert; Ruedy, Katrina; Kollman, Craig; Tomlinson, George; Murphy, Helen R.; on behalf of the CONCEPTT Collaborative Group Author Information Department of Medicine (D.S.F.) and Department of Obstetrics & Gynecology (K.E.M.), Sinai Health System; Lunenfeld-Tanenbaum Research Institute (D.S.F., K.E.M.); Department of Medicine, University of Toronto (D.S.F., K.E.M., G.T.), Toronto, Ontario; Department of Medicine, University of Calgary, Calgary, Alberta (L.E.D.), Canada; Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau CIBER-BBN, Barcelona, Spain (R.C., A.d.L.); Department of Women and Children's Health, St Thomas' Hospital (H.R.M.) and Diabetes Research Group, Faculty of Life Sciences and Medicine (S.A.A., K.F.H.), King's College London; Diabetes Service, Division of Urgent Care, Planned Care and Allied Critical Services, King's College Hospital NHS Foundation Trust (K.F.H.), London, United Kingdom; Sunnybrook Research Institute, Toronto, Ontario, Canada (E.A., J.F.R.B., J.J.S.); Department of Obstetrics and Gynecology, Helen Schneider Hospital for Women, Rabin Medical Center, Petah, Tikvah, Israel (M.H.); Division of Endocrinology, University of Southern California, Los Angeles (L.J.); Department of Chemistry, University of California, Santa Barbara (L.J.), CA; Department of Medicine, University of Ottawa, and The Ottawa Hospital, Ottawa (E.K.); Department of Obstetrics & Gynecology, McMaster University Hamilton (E.K.H.); Department of Medicine, St Joseph Health Care London (R.M.); Department of Medicine, University of Western Ontario (R.M.), London, Ontario, Canada; Wolfson Diabetes and Endocrine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (C.L.M., Z.A.S., H.R.M.); Nemours Children's Health System, Jacksonville (T.W.); Jaeb Center For Health Research, Tampa (R.O., K.R., C.K.), FL; Department of Medicine, University Health Network, Toronto, Ontario, Canada (G.T.); and Department of Medicine, University of East Anglia, Norwich, United Kingdom (H.R.M.) Obstetrical & Gynecological Survey: April 2018 - Volume 73 - Issue 4 - p 199-201 doi: 10.1097/01.ogx.0000532199.80944.24 Buy Metrics Abstract (Abstracted from Lancet 2017;390:2347–2359) It is established that optimal maternal glycemic control throughout pregnancy is associated with a decrease in adverse fetal outcomes. A proper glycemic index can be difficult to control in women with type 1 diabetes during pregnancy because of the complexity of insulin dose adjustment, gestational changes in insulin sensitivity, and day-to-day changes to insulin absorption in late pregnancy. Nationwide UK data show the rates of severe hypoglycemia, particularly in early pregnancy, are 5 times higher among pregnant women than nonpregnant and that only 40% of women with type 1 diabetes achieve target glycated hemoglobin (HbA1c) after 24 weeks of gestation. Continuous glucose monitoring (CGM) provides real-time quantitative information on the direction and rate of change of glucose levels. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.